Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease

Drugs and Aging

Volumn 19, Issue 3, 2002, Pages 203-215

  Farcnik, Karl ^a   Persyko, Michelle S ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; NEUROLEPTIC AGENT; RIVASTIGMINE; TACRINE; VELNACRINE;

AGING; ALZHEIMER DISEASE; AMNESIA; BEHAVIOR DISORDER; CAREGIVER; COGNITION; DAILY LIFE ACTIVITY; DISTRESS SYNDROME; HUMAN; LIVING WILL; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REVIEW; SOCIAL PSYCHOLOGY;

EID: 0036282572     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219030-00004     Document Type: Review

References (89)

1. Patterns of caring for people with dementia in Canada
2. Relatives of the impaired elderly: Correlates of feelings of burden
3. Caregiver well-being: A multidimensional examination of family caregivers of demented adults
4. Support for caregivers of persons with Alzheimer's disease: An evaluation of the effectiveness of the Diner's Club program
5. The economic burden of Alzheimer's disease care
6. Costs of dementia and dementia care: A review
7. Support of families
8. Relation between severity of Alzheimer's disease and costs of caring
9. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes
10. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health
11. Predictors of decreased self-care among spouse caregivers of older adults with dementing illnesses
12. Predicting caregiver burden and depression in Alzheimer's disease
13. General and specific events and depressive symptoms in Alzheimer's disease caregivers
14. Behaviour disturbance and other predictors of caregiver burden in Alzheimer's disease
15. Factors determining the decision to institutionalize dementing individuals
16. Behavioural problems and distress among caregivers of people with dementia
17. Coping with specific stressors in Alzheimer's disease caregiving
18. The measurement of caregiver outcomes in Alzheimer disease research
19. Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention
20. Caregiving and the stress process: An overview of concepts and their measures
21. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The neuropsychiatric inventory caregiver distress scale
22. Alzheimer's disease: The unpaid burden of caring
23. A meta-analytic review of interventions for caregiver distress: Recommendations for future research
24. A family intervention to delay nursing home placement of patients with Alzheimer disease: A randomized controlled trial
25. The burden of families coping with the mentally ill: An invisible crisis
26. Burden: A review of measures used among caregivers of individuals with dementia
27. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia
28. The screen for caregiver burden
29. Caregiving hassles scale: Assessing the daily hassles of caring for a family member with dementia
30. Application of a multidimensional caregiver burden inventory
31. The caregiver activity survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer's disease
32. The caregiver reaction assessment (CRA) for caregivers to persons with chronic physical and mental impairments
33. Measuring behavioral disturbance of elderly demented patients in the community and its effects on relatives: A factor analytic study
34. Validation of a caregiver strain index
35. TRIMS behavioral problem checklist (BPC)
36. The impact of dementia on the family
37. Families caring for elders in residence: Issues in the measurement of burden
38. Caregiving and the experience of subjective and objective burden
39. Medical school pressures and their relationship to anxiety
40. The caregiver activity survey (CAS): Longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease
41. Assessment of behavioral problems in dementia: The revised memory and behavior problems checklist
42. A new rating scale for Alzheimer's disease
43. Measurement of quality-of-life changes in patients with Alzheimer's disease
44. Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability
45. Validity and reliability of the Alzheimer's disease co-operative study: Clinical global impression of change
46. An inventory for measuring depression
47. A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
48. The efficacy and safety of donepezil in patients with Alzheimers disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
49. A randomized trial evaluating the efficacy and safety of ENA-713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
50. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
51. A 5-month, randomized, placebo-controlled trial of galantamine in AD
52. Galantamine: Therapeutic effects beyond cognition
53. Effect of tactine on behavioral symptoms in Alzheimer's disease: An open-label study
54. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
55. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living
56. Metrifonate therapy in Alzheimer's disease: A pooled analysis of four randomized, double-blind, placebo-controlled trials
57. Metrifonate: A new agent for the treatment of Alzheimer's disease
58. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: Results from the MALT clinical trial
59. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease
60. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine
61. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
62. Donepezil provides benefits in global function in moderate to severe Alzheimer's disease
63. Donepezil treatment in patients with moderate to severe Alzheimer's disease may reduce caregiver stress
64. Rivastigmine provides behavioral benefits to Alzheimer disease patients residing in a nursing home: Findings from a 26-week trial
65. Use of psychoactive medication and the quality of care in rest homes: Findings and policy implications of a statewide study
66. A longitudinal study of psychotropic prescriptions in a teaching nursing home
67. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia
68. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
69. Behavioural disorders in demented elderly patients
70. The recognition, assessment, and management of dementing disorders: Conclusions from the Canadian consensus conference on dementia
71. Non-pharmacologic approaches to behavior
72. The family caregiver's role in Alzheimer's disease
73. Stress reduction for family caregivers. Effects of daycare use
74. Efficacy of a support group programme for caregivers of demented patients in the community: A randomized controlled trial
75. Cost effectiveness of a training program for dementia carers
76. Caregiver distress and behavioral symptoms
77. Towards a science of Alzheimer's disease management: A model based upon current knowledge of retrogenesis
78. Systematic implementation of an advance directive program in nursing homes: A randomized controlled trial
79. Functional assessment tools and their use in long term management of Alzheimer's disease
80. The revised caregiver burden scale: A preliminary evaluation
81. Economic evaluation of donepezil for Alzheimer's disease in Canada
82. Assessing the societal impact of acetylcholinesterase inhibitor therapies